Dissecting NGLY1 deficiency

Collaborators: Carolyn Bertozzi & Lars Steinmetz

Background

NGLY1 Deficiency & The Grace Science Foundation

Over 8,000 rare diseases are estimated to affect more than 350 million people worldwide, and treatment strategies are often not available. In 2014, Grace Wilsey was diagnosed with N-Glycanase-1 (NGLY1) deficiency, which is a rare disease which is diagnosed in less than 50 other cases. Her parents, Matt and Kristen Wilsey, dedicated their lives to establishing the Grace Science Foundation: a worldwide team of researchers who are committed to finding a cure for NGLY1 deficiency and pioneering methods for identifying, treating and ultimately curing other rare diseases in the process.

Project

Rare disease biology - dissecting NGLY1 deficiency

NGLY1 deficiency is a rare condition caused by loss of function mutations in the NGLY1 gene. Consequently, protein deglycosylation and degradation are impaired, leading to an accumulation of debris within cells. Symptoms of NGLY1 deficiency include impaired motor control, global developmental delay, seizures, and a lack of tear production called alacrima.

Led by the Grace Science Foundation, a consortium of researchers from academia and industry is searching for new therapeutic approaches to effectively manage and treat NGLY1 deficiency. Within this consortium, Dr. Carolyn Bertozzi and Dr. Lars M. Steinmetz are studying the impact of NGLY1 deficiency on the integrity of the proteasome. They have shown that functional NGLY1 is required for processing the transcription factor NFE2L1, and they hope to translate this finding into clinical applications in the future.

Find out more:

Are you interested in finding out more about the NGLY1 deficiency project? Would you like to help us study and find a cure for rare diseases?  Get in touch! We would love to hear from you.

News:

Meet the postdocs working on NGLY1 deficiency

June 14, 2018

Biobank, foundation team up to accelerate research into a rare disease

October 4, 2017